

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1430 Alexandria, Virginia 22313-1450 www.wopto.gov

ELECTRONIC

02/08/2011

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/599,819	10/11/2006	Richard Heng	33739-US-PCT	5179
75974 7590 902082011 NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 220 MASSACHUSETTS AVENUE CAMBRIDGE, MA 02139			EXAMINER	
			COLEMAN, BRENDA LIBBY	
			ART UNIT	PAPER NUMBER
			1624	
			NOTIFICATION DATE	DELIVERY MODE

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

NIBR.MAILDATA@NOVARTIS.COM PATRICIA.HOFSTETTER@NOVARTIS.COM

Office Action Summary

Application No.	Applicant(s)	
10/599,819	HENG ET AL.	
Examiner	Art Unit	
Brenda L. Coleman	1624	

The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of them may be available under the provisions of 37 CPH 13/3(d). In or event, however, may a reply be limely filed after SIX (6) MONTHS from the mailing date of this communication. The six of the second seco					
Status					
1) Responsive to communication(s) filed on <u>08 December 2010</u> .					
2a)☑ This action is FINAL. 2b)☐ This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4)⊠ Claim(s) 1-5.7,11 and 17-20 is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5)⊠ Claim(s) <u>1.3.4.11 and 17-19</u> is/are allowed.					
6) Claim(s) 2.5.7 and 20 is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or election requirement.					
Application Papers					
9) ☐ The specification is objected to by the Examiner.					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:					
 Certified copies of the priority documents have been received. 					
Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s)					
10 Notice of References Cited (PTO-892) 4 Interview Summary (PTO-413) 21 1-Notice of Draftcorson's Fatent Drawing Review (PTO-943) Paper N-(s)/Môil Drin.					

Attachment(s)	
1) Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413)
2) Notice of Draftsperson's Patent Drawing Review (PTO 948)	Paper No(s)/Mall Orte
Information Disclosure Statement(s) (PTO/SB/08)	 Notice of Informal Patent Application
Paper No(s)/Mail Date	6) Other:

Page 2

Application/Control Number: 10/599,819

Art Unit: 1624

DETAILED ACTION

Claims 1-5, 7, 11 and 17-20 are pending in the application.

This action is in response to applicants' amendment filed December 8, 2010.

Claims 1, 2, 4, 5, 7, 17 and 20 have been amended.

Response to Amendment

Applicant's amendments filed December 8, 2010 have been fully considered with the following effect:

- 1. The applicants' amendments and arguments are sufficient to overcome the 35 U.S.C. § 112, second paragraph rejections labeled paragraphs 1a), b), c), i), j), k), m), n), o), p), q), r), s), x), y), z), aa), bb), cc), gg), hh), ii), ww) and yy) in the last office action, which are hereby **withdrawn**. However, with regards to the 35 U.S.C. § 112, second paragraph rejections labeled paragraph 1l) in the last office action, the applicant's amendments have been fully considered but they are not persuasive.
 - i) The applicants' stated that claims 1, 2, 4 and 5 have been amended to better define the invention. However, the definition of R1 in claim 2 still contains an "optionally" substituted sulfonyl which leaves the moiety -SO₂- when there is no substituent.

Claim 2 is rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, for reasons of record and stated above.

Application/Control Number: 10/599,819 Page 3

Art Unit: 1624

2. The applicants' amendments are sufficient to overcome the 35 U.S.C. § 112, first

paragraph rejection labeled paragraph 2) in the last office action, which is hereby

withdrawn.

3. The applicants' amendments and arguments are sufficient to overcome the 35

U.S.C. \S 112, second paragraph rejections labeled paragraphs 3a), b) and c) in the last

office action, which are hereby withdrawn.

In view of the amendment dated December 8, 2010, the following new grounds of rejection apply:

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

- 4. Claims 5, 7 and 20 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The following reason(s) apply:
 - a. Claim 5 is vague and indefinite in that it is not known what is meant by C_{2.7} alkyenyl where all of the other occurrences where corrected by the amendment filed December 8, 2010.

Claim Objections

 Claim 7 is objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim must be stated in the alternative. See MPEP § 608.01(n). Application/Control Number: 10/599,819

Art Unit: 1624

Allowable Subject Matter

6. Claims 1, 3, 4, 11 and 17-19 are allowed. None of the prior art of record or a search in the pertinent art area teaches the compounds, compositions, process of preparing and method of use of the 3-oxa-7-aza-bicyclo[3.3.1]non-7-yl or 3-oxa-7,9-diaza-bicyclo[3.3.1]non-7-yl compounds of formulae I. II as claimed herein.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brenda L. Coleman whose telephone number is 571-272-0665. The examiner can normally be reached on 9:30-6:00.

Art Unit: 1624

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Brenda L. Coleman/ Primary Examiner, Art Unit 1624